New Resource from NYC Medical Malpractice Attorney Jonathan C. Reiter Now Available
New York City, NY, June 01, 2025 (GLOBE NEWSWIRE) — In a healthcare system where medical errors rank as the third leading cause of death in America, acclaimed NYC trial attorney Jonathan C. Reiter is jolting listeners from passive acceptance to active vigilance with his groundbreaking new podcast series, 'Understanding Medical Malpractice and Its Impact.'
The podcast transforms listeners' mental state from relaxed inattention to focused engagement, delivering critical insights for patients navigating the aftermath of medical negligence – from recognizing when standards of care have been breached to understanding the complex legal landscape of pursuing justice.
'Most patients don't realize they're victims of malpractice until it's almost too late to take action,' says Reiter, whose decades of experience have secured millions in compensation for victims of medical negligence. 'This podcast bridges the knowledge gap that exists between medical professionals and the patients they serve.'
The debut episode explores the shocking prevalence of preventable medical errors, including surgical mistakes, misdiagnosis, birth injuries, and medication errors. Reiter provides listeners with a comprehensive framework for identifying potential malpractice and outlines the critical steps patients should take immediately following suspected negligence.
'Understanding the statute of limitations is crucial,' Reiter emphasizes. 'In New York, patients typically have just 2.5 years from the date of malpractice to file a lawsuit, but many victims spend much of that time simply trying to understand what happened to them.'
Future episodes will feature interviews with medical experts, patient advocates, and survivors of medical negligence, creating a multifaceted resource for patients and their families. The podcast also examines the broader impact of medical malpractice on the healthcare system and explores potential reforms.
With his characteristic clarity and compassion, Reiter transforms complex legal concepts into accessible guidance for listeners. The podcast serves as a natural extension of his commitment to patient advocacy and healthcare accountability.
'Understanding Medical Malpractice and Its Impact' is available now on the website here.
About Jonathan C. Reiter
Jonathan C. Reiter Law Firm – Top NYC Medical Malpractice Lawyer, Releases New Legal Resource
Jonathan C. Reiter is a prominent New York City medical malpractice and personal injury attorney. With over 30 years of experience, he has established himself as one of NYC's premier legal advocates for victims of medical negligence. His firm, the Jonathan C. Reiter Law Firm, PLLC, has secured substantial verdicts and settlements for clients affected by medical errors, helping them rebuild their lives after devastating injuries.
Media Contact:
Jonathan C. Reiter Law Firm, PLLC
www.jcreiterlaw.com
T: 212-736-0979
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET. The live and archived webcast of the panel will be accessible from the company's website at About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contacts – Ultragenyx Pharmaceutical, Higa ir@
Yahoo
an hour ago
- Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.07 per share, which is equal to the closing price of the company's common stock on May 30, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). About Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc.). Investor and Media Contact: Scott YoungVice President, Investor Relations and Corporate Communicationsinvestors@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ('Olema' or 'Olema Oncology', Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $4.38 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on June 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit Media and Investor Relations ContactCourtney O'KonekVice President, Corporate CommunicationsOlema Oncologymedia@ in to access your portfolio
